1. Corporate Presentation
March 2017

2. Disclaimer Intro March 2017
This corporate presentation (the “Presentation”) has been prepared by ADOCIA (the “Company”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompanying this document provided by the Company, any question and answer session following that oral presentation and any further information that may be made available in connection with the subject matter contained herein.
The information and opinions contained in this document speak only as of the date of the Presentation and may be subject to significant changes. The Company does not undertake any obligation to update the information or opinions contained herein in light of any new information or future developments.
The information contained in the Presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not be held liable for any loss or damage that may arise from the use of the Presentation or the information or opinions contained herein.
The Presentation contains information on the Company’s markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company’s own estimates. Investors should not base their investment decision on this information.
The Presentation does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris. The Company’s annual reference document for the year ended December 31, 2015 filed with the French Autorité des marchés financiers (the “Financial Markets Authority”) on April 8, 2016 and available in an English convenience translation on the Company’s website, in particular its Risk Factors section found in Section 4, as well as any other of its periodic reports should be carefully reviewed. Information and other data appearing in such publications, and certain figures and numbers appearing in the Presentation have been rounded. Consequently, the total amounts and percentages appearing in tables and elsewhere may not necessarily equal the sum of the individually rounded figures, amounts or percentages.
The Presentation contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Factors that may cause actual results to differ materially from those contained in any forward-looking statements include the uncertainties relating to research and development, results of clinical trials, success of the Company’s collaboration agreements and decisions by regulatory authorities regarding approval of the Company’s products, as well as those discussed or identified in the public filings made by the Company with the Financial Markets Authority. Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Company's future performance and the Company’s actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates, may differ materially from those proposed or reflected in the forward-looking statements contained in the Presentation. Even if the Company’s financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in the Presentation, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of the Presentation.
The Presentation does not constitute an offer to sell or subscribe or a solicitation to purchase or subscribe for securities in France, the United States or any other jurisdiction. Securities may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration thereunder. No public offering of securities will be conducted in France or abroad prior to the delivery by the Financial Markets Authority of a visa on a prospectus that complies with the provisions of Directive 2003/71/CE as amended. No public offering of securities is contemplated in France or any jurisdiction outside France.
The distribution of the Presentation may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. All persons accessing the Presentation are deemed to agree to all the limitations and restrictions set out above.
March 2017

3. Management Team adocia Gérard Soula Olivier Soula Valérie Danaguezian
PhD, MBA
Olivier Soula
Valérie Danaguezian
Rémi Soula
Steve Daly
President & CEO
Co-founder
Deputy General Manager,
R&D Director
Chief Financial Officer
Director of BD & IP
US General Manager
March 2017

4. ADOCIA in summary Adocia1
Specialist in protein-based diabetes treatments, providing innovative therapeutic options 2
Business model based on already-approved proteins, enhanced with BioChaperone® 3
Phase 3 – ready ultra-rapid insulin BioChaperone Lispro 4
Strong pipeline with new clinical launches expected in 2017 5
Proven management team with successful track-record 6
Solid cash position
March 2017

5. Corporate Fact Sheet adocia
Focused on Diabetes treatment using already-approved therapeutic hormones to address core-defects:
BioChaperone prandial insulins: BC Lispro (Phase 2) & HinsBet (Phase 2)
BioChaperone Insulins Combo (Phase 2)
New programs: BC Glucagon, BG Glargine GLP-1 combos, BC Lispro combos (preclinical)
Founded in 2005 by Gérard, Olivier & Rémi Soula
Listed on Euronext (ADOC) - Market Cap €142M*; Share Price: €20.70* (from IPO Feb 2012)
Cash position end of December 2016 :€58M (€85M raised to date)
Experienced executive team; 125 employees including 46 PhDs, MDs, PharmDs
BioChaperone® unlocks the potential of hormones and their combinations
Expanding treatment options by solving difficult formulations challenges
30 patent families ; validated in 15 human clinical trials to date
March 2017
* As of Feb 10, 2017

6. Our mission is dedicated to the treatment of diabetes
ADOCIA
Our mission is dedicated to the treatment of diabetes
Provide people with more physiologic treatments of diabetes
in a simple and affordable way
to help them avoid severe consequences of their disease
March 2017

7. Supported by a Top-Tier Medical Advisory Board
adocia
Broad portfolio addresses the diverse medical needs of diabetes patient populations
Clinical programs
Preclinical programs
In vitro PC
Phase I/II
Phase III
In vitro PC
Phase I/II
BC Lispro U100
BC Glucagon
BC Lispro U200
BC Gla Lira
BC Gla Lispro
BC Gla Dula
(BC Combo)
BC Lis Pram
HinsBet U100
BC Lis Exe
HinsBet U500
Supported by a Top-Tier Medical Advisory Board
March 2017

8. There remains a real medical need in diabetes
on insulin
415M1
people with diabetes in 2015
Despite 100 years of medical treatment, long-term consequences of diabetes remain a major issue
People with T1D in particular, are still confined to insulin treatment ‘alone’
There is a need to address the underlying complexity of diabetes
With more granularity
In a simple way to ensure patient engagement
79%3
live with severe complications
1 International Diabetes Federation, Diabetes Atlas 2015; 2 Estimate based on 25% of diabetes patients having access to care, of which ~25% use insulin, as per Novo Nordisk, Full Year 2014 Investor presentation ; 3 Hazel- Fernandez & al; Am J Manag Care Patients with a Diabetes Complications Score Index of 1 or more, in a sample of 333,576 Medicare advantage plan members diagnosed with diabetes.
March 2017

9. DIABETES
Sustainability of the healthcare systems raises a major cost-effectiveness challenge
Need for sustainability of healthcare system, especially in pandemic disease like diabetes:
Pressure on drug pricing
Advent of biosimilar drugs
Emergence of value-based models
Volume will drive growth in the diabetes market
Currently, millions of patients do not yet benefit from innovation due to cost hurdles
$245B1
Diabetes -related costs (2012, US)
$29B1
for antidiabetic drugs and supplies (12% of total, 2012, US)
March 2017
1 American Diabetes Association, “Economic Costs of Diabetes in the US in 2012”, 2013.

10. 3 pillars support the future of diabetes treatment
Affordability
Patient engagement
More physiologic
approaches
Ultra-rapid insulin action
Combo of synergistic hormones
Synchronized hormonal actions
Enable simple combinations
Use of approved hormones vs. NCE
Shorter clinical development
March 2017

11. [BioChaperone® Hormone]
adocia
BioChaperone® unlocks the potential of hormones and their combinations in a cost-effective way
BioChaperone®
Hormones
Simple formulation approach
Leverage existing manufacturing capabilities
Easy implementation
32 patent families
On BC molecules and formulations
1st expiry date 2033
(insulin, GLP-1 RA, amylin, glucagon)
(library of molecules)
[BioChaperone® Hormone]
Complex
Accelerated absorption
Improved solubility
Improved stability
Potential benefits
March 2017

12. Formulation enables affordable innovation
ADOCIA
Formulation enables affordable innovation
With BioChaperone®, Adocia develops innovative and cost-effective new treatments for diabetes
Innovative formulation allows opportunity to improve and combine approved hormones with established track-records
Enhance performance of individual hormones
Enable combination of “un-combinable” hormones
This approach to innovation has the following advantages:
Reduced level of risk
Shorter clinical development
Lower investment levels (clinical and manufacturing)
March 2017

13. adocia
Lean business model provides innovative treatments in a competitive landscape
Adocia licensing business model targets diabetes players
Early licensing opportunities allow for faster return on investment
Adocia is evolving towards a more sustainable, higher-value licensing business model
Shift from « proof-of-concept » to late-stage, Phase 3 ready projects
Developing different risk-reward sharing strategies
March 2017

14. BioChaperone INSULIN Clinical programs
March 2017

15. A more physiologic short-acting insulin for better outcomes
Bc lispro
A more physiologic short-acting insulin for better outcomes
BioChaperone® Lispro U100
Potential benefits
$7B
Prandial insulin market (2015)1
More time-in-range (less hypoglycemia and less hyperglycemia)
More flexible dosing options at mealtime
BioChaperone® Lispro U200
March 2017
1 Source: Adocia estimates based on major companies annual reports, 2015

16. Faster BC Lispro improves glycemic control
Post-meal glycaemia in T1D
Accelerated absorption and better post-prandial control for BC Lispro U100 vs. Humalog observed across T1D & T2D patients & devices
BC Lispro U200 is the most advanced ultra-rapid concentrated insulin in development. Potential for co-filing with U100
BC Lispro has a complete dossier to enter into phase 3
Adocia is actively looking a potential partner
AUC0-2h:
-61%*
Liquid meal
+ Insulin s.c.
Trial in 38 subjects with type 1 diabetes (NCT# ) ; *CI-95% for LSM ratio
These results were the subject of an oral presentation by Dr Tim Heise (Profil Neuss) during the 76th Scientific Sessions of the American Diabetes Association (June 2016).
March 2017
For more detailed results, cf. Appendix

17. Key clinical results supporting potential entry into Phase 3
Bc lispro
Key clinical results supporting potential entry into Phase 3
Consistent results obtained in 210 people with T1D & T2D across common administration devices
Repeated administration in T1D (solid meal test; March 14, 2016 ; NCT , 36 patients)
31% reduction in blood glucose excursion over first 2 hours vs. Humalog injected at mealtime at beginning of treatment 42% reduction at end of treatment
Repeated administration in T2D (solid meal test; April 27, 2016; NCT , 51 patients)
22% reduction in blood glucose excursion over first 2 hours vs. Humalog injected at mealtime
Insulin pump therapy in T1D (solid meal test; December 15, 2016; NCT , 44 patients)
Acceleration demonstrated in 2 pumps & insulin syringe compared to Humalog injected at mealtime
Pilot bioequivalence (BE) study U200/U100 (December 11, 2015; NCT , 26 volunteers)
Predefined criteria for BE were met
Study in healthy Japanese subjects (May 31, 2016; NCT , 15 patients)
Confirmed BC Lispro PK/PD profile, allowing Japanese patients inclusion in Phase 3
March 2017

18. Bc combo
A true combination of two gold standard insulins - glargine as basal and lispro as prandial
Once-a-day 6 10 14 18 22 2
Insulin lispro
Humalog® 6 10 14 18 22 2
BioChaperone® COMBO = +
Twice-a-day 6 10 14 18 22 2
Insulin glargine
Lantus® 6 10 14 18 22 2
Schematic PK representations
Twice-a-day
vs. Premix insulin 6 10 14 18 22 2
March 2017

19. BioChaperone® Gla Lispro
Bc combo
Adocia is developing a simple 2-in-1 option for tight basal and prandial control
$5B
Premix insulin market (2015)1
Potential benefits*
As simple as premix with better control and less hypoglycemia
Less injections than Basal/Bolus with similar control
One co-pay and use of “off-patent” insulins
BioChaperone® Gla Lispro
(BC Combo)
*As demonstrated clinically by the only comparable approved product, Ryzodeg (Novo Nordisk)
March 2017
1 Source: Adocia estimates based on major companies annual reports, 2015

20. Bc combo T1D
BC Combo has shown superior prandial and basal control compared to premix insulin in people with T1D
Post-meal glycemia in T1D
In T1D, BC Combo showed vs. HumalogMix 75/25:
Less hyperglycemia (faster-acting)
Less hypoglycemia (lower late prandial effect)
Potential for once-a-day administration (24h basal action in a clamp trial) with most major meal coverage
Individualized doses
∆AUC0-2h
-24%1
Less hyper
BGmin +30%2
Less hypo
Liquid meal
+ Insulin s.c.
Trial in 28 people with T1D (NCT# ); 1 p=3.10-3;2 p=8.10-3
These results were presented by Dr Steve Edelman (UCSD) during the 76th Scientific Sessions of the American Diabetes Association (June 2016).
March 2017
For more detailed results, cf. Appendix

21. Bc combo t2dm
BC Combo 75/25 confirmed its promising profile compared to premix insulin in people with T2D
Glucose Infusion Rate in T2D (clamp)
BC Combo has the potential to offer competitive pricing compared to Novo Nordisk’s Ryzodeg®
Program to achieve ready-to-phase 3 stage to reach next inflexion point
3 successful clinical studies (T1D & T2D)
Ongoing meal-test study in T2D
Results expected Q2 17
Planned dose-response study in T1D
Expected to start Q2 17
Planned Outpatient study in T2D
Expected to start Q4 17
Sharp transition
Fast
24hr +
Trial in 24 people with T2D (NCT# ).
These results were the subject of poster commented by Dr Eda Cengiz (Yale School of Medicine) during the 76th Scientific Sessions of the American Diabetes Association (June 2016).
March 2017
For more detailed results, cf. Appendix

22. Human prandial insulin market (2015)1
hinsbet
Adocia intends to deliver affordable prandial insulin to price-sensitive populations
HinsBet® U100
Potential benefits
Affordable prandial insulin
Dosing closer to mealtime
$1B
Human prandial insulin market (2015)1
HinsBet® U500
March 2017
1 Source: Adocia estimates based on major companies annual reports, 2015

23. Early Glucose Infusion Rate (U100)
hinsbet
HinsBet displays similar early action to fast-acting insulin analog in T1D patients
Early Glucose Infusion Rate (U100)
Meal-test study in 36 T1D confirmed PD profile in first hour1 (Oct 2016)
During first hour after the meal, HinsBet:
Significantly reduced glucose excursion vs Humulin (p=0.0002)
Was not significantly different from Humalog (p=0.5373)
Exploring licensing options in emerging markets
1Meal-test study in 36 subjects with type 1 diabetes (NCT# ). Subjects received individualized single doses of HinsBet, regular human insulin (Humulin) and rapid-acting analog insulin lispro (Humalog) immediately before ingesting a standardized mixed meal. Detailed results remain under embargo until publication at a major diabetes conference.
PK/PD clinical trial in 36 subjects with type 1 diabetes (NCT# ).
March 2017

24. New programs
March 2017

25. How to potentialize insulin action?
Multi- hormonal
How to potentialize insulin action?
GLP-1
Amylin
In combination
Insulin
BC Glargine GLP-1 BC Lispro Pramlintide BC Lispro Exenatide
Efficacy
Glucagon
In a dual-chamber pump
Safety
BC Glucagon + Insulin
March 2017

26. diabetes
Among a multitude of metabolic hormones, 4 classes have been approved for the treatment of diabetes
Pancreas
Produces insulin, amylin & glucagon
Multiple targets of action of:
insulin
amylin (pramlintide)
GLP1 (GLP1-RA)
glucagon
Intestines
Produce GLP-1
March 2017

27. In T1D, hormonal pattern is severely disrupted
In healthy people, a time-sensitive hormonal pattern maintains normoglycemia
diabetes
Schematic representation of hormonal pattern1
Insulin
Amylin
Glucagon
GLP-1
Meal
Healthy
Meal
Insulin
Amylin
Glucagon
GLP-1
With Type 1 diabetes (T1D)
Level of secretion (relative scale) 1 2 3 4 5 6 1 2 3 4 5 6
Time
Insulin, Amylin and GLP-1 are secreted
X Glucagon is suppressed
In T1D, hormonal pattern is severely disrupted
1 Source: Adocia, adapted from Toff-Neilsen et al, J. Clin Endocrinol Metab 2001;86: ; Cummings DE et al, Diabetes 2001;50: ; Aronoff SL et al , Diabetes Spectrum 2004; 17(3):
March 2017

28. People with T1D need multi-hormonal treatment to improve long-term outcomes
Bc prandial combos
Complications1
heart disease, retinopathy, nephropathy, blindness, amputations…
Industry focused on developing multi-hormonal treatments for T2D
Established benefit of hormonal combinations in T2D
T1D are insulin, amylin and GLP1-deficient
Insulin alone is life-saving, but insufficient to prevent long-term complications despite optimal use
Pramlintide is the only other hormone approved for T1D, but puts disproportionate burden on patients (up to 7+ injections/day total)
No combination is approved for T1D
Tighter glycemic control lowers the risk of severe complications1
65%2
of US adults with T1D are overweight or obese
36%3
of children with T1D are overweight or obese
1 DTTC study, NEJM, 1993, 329(14); EDIC study NEJM, 2005, 353(25) 2 Conway et al, Diabetes Med 2010 April; 27(4): BMI>25, Data for period. 3Du Bose et al, J Ped 2015, data for Germany & the USA, WHO BMI categories.
March 2017

29. Glucagon is needed to address hypoglycemia
Bc glucagon
Glucagon is needed to address hypoglycemia
Insulin prevents hyperglycemia (e.g. after meals)
Glucagon prevents hypoglycemia (e.g. during exercise) by raising the blood glucose level
Human glucagon is the only approved rescue treatment against severe hypoglycemia
But human glucagon is unstable in solution requiring reconstitution of lyophilized product in emergency situations
A ready-to-use aqueous solution of human glucagon is needed to improve treatment of hypoglycemia
INSULIN
Blood glucose concentration
GLUCAGON
March 2017

30. BioChaperone® Human Glucagon DHAP : Dual-hormone artificial pancreas
Bc glucagon
Adocia aims to greatly enhance insulin pump therapy with stable and soluble human glucagon
CGM
Insulin
Glucagon *
Potential benefits
Relieve patient from risk of hypoglycemia, especially at night
More time-in-range (less hypoglycemia & less hyperglycemia)
More freedom to live “normal” everyday life
BioChaperone® Human Glucagon
DHAP : Dual-hormone artificial pancreas
Automated administration of insulin and glucagon under continuous glucose monitoring (CGM)
March 2017
* For illustration purposes only

31. BC glucagon
DHAP is a promising system to achieve truly automated closed-loop glycemic control
39 individual CGM traces (T1D)
Insulin only (CSII)
Bionic pancreas
(DHAP)
Significantly improved control with BetaBionics Ilet dual-chamber system (insulin + reconstituted Lilly Glucagon®) in pilot clinical study :
Better glycemic control, less intrasubject and intersubject variability compared to usual care
Less hypoglycemia than usual care
Achieved in the home setting, meal announcements were optional. Device worn 24h/day for 11 days.
March 2017
El Khatib et al, 77-OR, ADA 76th Scientific Sessions June 10-14th 2016, USA. Multicenter, randomized, CSII-controlled clinical trial in 39 adults with T1D. Russell et al, The Lancet (2016) 4(3):

32. Adocia develops an aqueous human glucagon for use in a DHAP system
BC glucagon
Adocia develops an aqueous human glucagon for use in a DHAP system
Mean blood glucose (pigs)
BC Human Glucagon showed similar action on blood glucose compared to Glucagen® during the first 3 hours in preclinical studies
BC Human Glucagon is soluble and stable at pH 7
3 weeks stability at 37°C
Development of standard concentration (1 mg/mL) for rescue and more concentrated formulations for DHAP
First-in-man study expected to start in Q2 2017
N=7 pigs. Cross-over design BC Glucagon (1 mg/mL) vs. GlucaGen® (Novo Nordisk, 1 mg/mL, reconstituted ex-temporane.)
March 2017

33. BioChaperone® Glargine Dulaglutide BioChaperone® Glargine LiraglutideBC
Glar GLP-1
Adocia is developing efficient and affordable intensification options over basal insulin for T2D
BioChaperone® Glargine Dulaglutide
Potential benefits*
Better control than basal alone
Fewer side effects than each product separately
Weight neutral
Only 1 daily injection
$7B
Forecasted Basal-GLP1 market
( )1
BioChaperone® Glargine Liraglutide
*As demonstrated clinically by approved products Xultophy® (IDegLira) & Soliqua® (IGlarLixi)
March 2017
1 Source: Leerink forecasts, October 6, 2016

34. Patients on basal insulin are not adequately controlled1BC
Glar GLP-1
Two injectable combos for better and/or more affordable intensification options in T2D
50%1
Patients on basal insulin are not adequately controlled1
Adocia is currently developing 2 products:
BC Glargine Liraglutide, potential for competitive pricing, based on use of off-patent proteins
BC Glargine Dulaglutide, potential for best-in-class performance, based on excellent profile of dulaglutide and glargine.
First stability and preclinical results are promising
First-in-man study expected on one product to start in , based on positive CMC & preclinical results
Xultophy® (IDegLira, NVO) & Suliqua®/Soliqua® (IGlarLixi, SAN) approved in EU & US (2016)
« All-in-1 »
1 product
1 injection
1 co-pay
1 Sanofi, JP Morgan Healthcare Conference Presentation , San Francisco, January 12, 2015.
March 2017

35. BioChaperone® Lispro Pramlintide BioChaperone® Lispro Exenatide
BC Lispro combos
Enabling new prandial insulin combinations with already proven medical benefits
BioChaperone® Lispro Pramlintide
Potential benefits*
Better control than prandial insulin alone
Weight loss or weight neutrality
Fewer side effects than each product separately
No increase in injection burden
BioChaperone® Lispro Exenatide
*As demonstrated clinically by co-administration of approved products insulin & pramlintide in people with T1D and insulin & exenatide in people with T2D
March 2017

36. pramlintide
Pramlintide (TID) clinically proven synergistic benefits with mealtime insulin in people with T1D
Adocia intends to develop easy-to-use combinations of insulin/pramlintide for people with T1D
Blood glucose control (T1D)
-22%*
-3 kg*
Prandial suppression of glucagon
Slowed gastric emptying
Appetite reduction
-0.2%*
-0.2%*
Guthrie R et al Diabetes 2005, 54(Suppl 1):A118 T1D, N = 265 at baseline; 6-month data; mean (SE);
*: P <.05. See also Pullman J et al Vasc Health Risk Manag. 2006, 2 (3), and in T2D only: Karl D, et al. Diabetes Technol Ther 2007; 9(2):
March 2017

37. Delta glucose in blood after a mixed meal
exenatide
Exenatide clinically proven synergistic benefits with mealtime insulin in people with T1D
Delta glucose in blood after a mixed meal
150
100 50
-50
-100
200
300
Delta glucose (mg/dL)
insulin
insulin + exenatide 1.25µg
insulin + exenatide 2.5µg
Time (min)
Exenatide on top of prandial insulin in T1D has shown:
Improved glycemic control
Insulin dose reduction of 20%
GLP-1 have also demonstrated both in T1D and in T2D:
Reduction in HbA1c after 6 months
Weight loss compared to insulin alone
Fewer side effects, especially hypoglycemia
Adocia to develop easy-to-use combinations of insulin/GLP-1 for people with T1D
Adapted from Raman VS, et al. Diabetes Care 2010 Jun; 33(6):
Pediatric patients with T1D on MDI (N = 8) received BYETTA (exenatide) 1.25 and 2.5 mcg pre-meal adjunctive to prandial insulin. Glycaemia was analyzed for 6 hours post-meal.
March 2017

38. Unlocking the potential of prandial insulin combinations
BC Lispro combos
unmixable
Prandial Insulin (Lispro)
Pramlintide or
Exenatide
Increases glucose disposal
Modulate glucose appearance
3 injections/day
2 or 3 injections/day
+ BioChaperone
BioChaperone Lispro Combos
3 injections/day or CSI
March 2017

39. BC Lispro Combos may restore the synergistic benefits of prandial hormones for people with T1D
BC Lispro Combos are potentially affordable options based on mature proteins:
BioChaperone has demonstrated ability to stabilize these combinations in aqueous solution against fibrillation at 4°C and 37°C.
BC Lispro Combos could be administered from a pen or a pump
Pump use may mimic normal physiology even more closely
Emerging T2D-friendly pumps may facilitate expanded use of BC Lispro Combos in T2D population
Insulin lispro +
Pramlintide
Exenatide
March 2017

40. Key financial elements
adocia
Key financial elements
Financial summary
Shareholders’ equity (November 30, 2016)
Analysts
Listed on Euronext Paris (ADOC)
6.9M shares outstanding
ADR program in the US (ADOCY)
Well capitalized €58M cash position (December 31, 2016)
€85M raised since inception
Long term debt:
€0.9M loan from BPI France (refundable in case of success)
€6.1M bank loan for purchase of Lyon headquarters building
Soula Family 22.0 %
Free Float (*)
60.3%
BPI 10.8%
Sham 4.7%
Viveris 1.0%
Oréo Finance 0.6%
Key managers 0.6%
Leerink (Seamus Fernandez)
Jefferies (Peter Welford)
Kepler Market (Arsène Guekam)
Invest Securities (Martial Descoutures)
Oddo (Sébatien Malafosse – Pierre Corby)
Louis Capital Partners (Pierre Vaurice)
(*) including US investors from March, 2015 private placement of 10% of the capital (KKR, Alken, BVF and others)
March 2017

41. Expected upcoming catalysts
adocia
Expected upcoming catalysts
Clinical programs
Preclinical programs
BC LISPRO
Phase 3-ready asset to be partnered
BC COMBO
Ongoing Phase 2a study in T2D results : Q2 17
Planned dose-response study in T1D: to start Q2 17
Planned outpatient study in T2D: to start Q4 17
HINSBET
Looking for a partner in regional markets
BC HUMAN GLUCAGON
First-in-man study : Q2 2017
BC GLARGINE DULA & BC GLARGINE LIRA
First-in-man study : 2017
BC LISPRO PRAMLINTIDE & BC LISPRO EXENATIDE
First-in-man study : Q4 17
March 2017

42. appendix
March 2017

43. Adocia is supported by a top-tier Medical Advisory Board
12 highly renowned international thought-leaders:
Dr. Jay Skyler, MD, Chairman, University of Miami (US)
Dr. Vanita Aroda, MD, MedStar Health Research Institute (US)
Dr. Bruce Bode, MD, Emory University (US)
Dr. John Buse, MD, PhD, University of North Carolina (US)
Dr. William Cefalu, MD, Louisiana State University (US)
Dr. Steven V. Edelman, MD, University of California at San Diego (US)
Dr. Dan Einhorn, MD, University of California at San Diego (US)
Dr. Vivian Fonseca, MD, Tulane University (US)
Dr. Irl Hirsch, MD, University of Washington (US)
Dr. Chantal Mathieu, MD, University Hospital of Leuven (Belgium)
Dr. Thomas Pieber, MD, Medical University of Graz (Austria)
Prof. Denis Raccah, MD, PhD, APHM (France)
March 2017

44. Results summary compared to Humalog U100 in T1DM subjects
Bc lispro
Results summary compared to Humalog U100 in T1DM subjects
294-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions
BioChaperone Lispro in comparison with Humalog showed:
Faster absorption
Faster-in (Early t[50%max], tmax, AUC0-30min)
Faster-out (Late t[50%max], AUC2- 8h)
Similar total exposure
Reduced post prandial glucose excursions
61% PPG reduction over the first two hours
Reduction of blood glucose by 42 mg/dL at 1 hour
Similar safety profile at single dose conditions based on local tolerance and number of hypoglycemic events
Comprehensive work to further evaluate BioChaperone Lispro ongoing, including a concentrated U200 formulation
Biochaperone Lispro: Shorter TMAX, Higher CMAX and Similar Exposure
Greater Earlier Exposure: Faster In
GeoLSM
BC Lispro
GeoLSM Humalog
Ratio [95%CI] BC Lispro/Humalog
Early t[50%max] (min) 18 29
0.63 [0.57; 0.70]
AUC0-30min (h*mU/L) 23 9
2.68 [2.18; 3.30]
AUC0-1h (h*mU/L) 76 50
1.52 [1.37; 1.67]
GeoLSM
BC Lispro
GeoLSM Humalog
Ratio [95%CI] BC Lispro/Humalog
Tmax (min) 47 62
0.75 [0.69; 0.83]
Cmax (mU/L)
117
104
1.13 [1.06; 1.20]
AUC0-8h (h*mU/L)
256
254
1.01 [0.97; 1.05]
Lower Late Exposure: Faster Out
Better Post Prandial Glucose Control
GeoLSM
BC Lispro
GeoLSM Humalog
Ratio [95%CI] BC Lispro/Humalog
Late t[50%max] (min)
135
160
0.85 [0.78; 0.91]
AUC2-8h (h*mU/L) 84
106
0.79 [ 0.72; 0.87]
BC Lispro
Humalog
Mean Difference
BG1h (mg/dL)
135
177 42
BG2h (mg/dL)
126
153 27
March 2017

45. Bc COMBO
Results summary compared to Conventional Lispro Mix 75/25 in T1DM subjects
295-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions
In this solid mixed meal study, BC Combo achieved more effective PPG control than lispro Mix:
Improved post-prandial blood glucose control
24% reduction in ΔAUCBG_0-2h
23 mg/dL decrease in maximum BG
24 mg/dL mean BG reduction at 1hr
Lower risk for delayed prandial hypoglycaemia
Less subjects with low BG < 63 mg/dL and 50 mg/dL
Less time spent in hypoglycaemia and more time spent in target glycaemia
Potential of BC Combo to improve post- prandial glucose control and lower risk of both hyperglycaemic and hypoglycaemic excursions will be investigated in further clinical studies
Mean Unadjusted BG Profiles ± SEM Over 6hr After s.c. Administration of Individualised Doses of BC Combo and Lispro Mix
Cumulative Percentage of Subjects With BG Values < 63 mg/dL (A) or < 50 mg/mL (B) Over the Course of the Meal Test
Demographic and Baseline Characteristics of the Study Population
Hypoglycaemic events
Parameter
Mean ± SD
Sex
Female: n-6 (21.4%) Male: n-22 (78.6%)
Diabetes Duration (years)
27.2 ± 11.5
Race
White 100%
BMI (kg/m2)
24.2 ± 2.1
Age (years)
45.9 ± 11.2
C-Peptide (nmol/L)
Height (cm)
177 ± 8
HbA1c (%)
7.33 ± 0.80
Weight (kg)
76 ± 10
Parameter
BC Combo
Lispro Mix
P-value
Subjects with at least one
hypoglycaemic event
7 / 27
15 / 28
Number of hypoglycaemic
events 12 29
event per subject 02
30 subjects screened, 28 randomised, 28 received lisproMix – 27 received BC Combo
Full analysis set n=28: 27 BC Combo – 27 lispro Mix (1 exclusion due to wrong dosing)
1 Chi-Square test
2 Median
3 Wilcoxon Signed Rank test
March 2017

46. Results summary compared to Humalog 75/25 in T2DM subjects
Bc COMBO
Results summary compared to Humalog 75/25 in T2DM subjects
942-P in 12-B Clinical Therapeutics/ New Technology-Insulins, June 11, 2016, 76th ADA Scientific Sessions
In this study, BC Combo demonstrated:
Greater early glucodynamic effect in first hour post dosing and faster time to maximum blood glucose lowering which is essential to achieve better post prandial blood glucose control
Lower late post prandial effect in comparison to Humalog Mix 75/25 which may reduce the risk of delayed post- prandial hypoglycaemia as shown in a meal test study in subjects with T1DM (ADA OR-295)
Higher late basal effect than Humalog Mix 75/25, similar to the separate injections, indicating that BC Combo could adequately provide both basal and prandial insulin requirements for a meal with only one injection per day
The results obtained in T2DM subjects replicate our findings in subjects with T1DM by demonstrating BC Combo’s favorable time-action profile over Humalog Mix 75/25
Smoothed GIR Profiles (0-30h) of 0.8 U/kg BioChaperone Combo, U/kg HumalogMix 75/25 and Separate Injections of 0.2 U/kg Lispro U/kg Glargine
Smoothed GIR Profiles (0-2h) of 0.8 U/kg BioChaperone Combo, 0.8 U/kg HumalogMix 75/25 and Separate Injections of U/kg Lispro U/kg Glargine
PD Parameters Based on Glucose Infusion Rate
BC Combo
Humalog Mix 75/25
P-value vs. BC Combo
Lispro _ glargine
Pramdial Phase (0.6h)
AUCGIR 0-1h [mg/kg]
88 (74)
29 (34)
<0.0001
58 (48)
0.0087
AUCGIR 0-2h [mg/kg]
294 (227)
174 (126)
0.0001
277 (184)
0.5227
AUCGIR 0-6h [mg/kg]
860 (536)
1011 (535)
0.0335
1121 (556)
0.0003
TGIRmax [h]
1.3 [1.2;5.1]
3.8 [1.8;6.0]
2.9 [1.4;4.9]
0.0057
Prandial – Basal Transition (6-12h)
AUCGIR 6-12h [mg/kg]
589 (275)
870 (501)
0.0002
630 (211)
0.3420
AUCGIR 6-24h [mg/kg]
1075 (615)
1481 (911)
1156 (551)
0.4522
Basal Phase (12-30h)
AUCGIR 12-18h [mg/kg]
342 (225)
473 (354)
0.0063
382 (221)
0.2156
AUCGIR 24-30h [mg/kg]
186 (133)
99 (102)
0.0105
174 (139)
0.6747
Overall
AUCGIR 0-30h [mg/kg]
2122 (1184)
2590 (1368)
0.0103
2451 (1071)
0.0124
Table shows arithmetic means (SD) except median [min;max] for TGIRmax
P-value from Hodges and Lehmann Estimates or (for AUCGIR 0-6h and AUCGIR 0-30h) from LS Means
March 2017

47. March 2017